Psoriasis drug guselkumab under microscope in new immune study
NCT ID NCT04645355
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is testing how the drug guselkumab affects the immune system in people with two types of psoriasis: plaque and guttate. Twenty-five adults will receive guselkumab injections over 44 weeks. Researchers will measure changes in immune cells in the skin to understand how the drug works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Guselkumab (a biologic drug that blocks IL-23, given as an injection)
- What this could lead to
- If successful, this could help explain why guselkumab works for different types of psoriasis, potentially leading to more personalized treatment.
- What could go wrong
- This is a small, early-phase study with only 25 people, so results may not apply to everyone. It is not designed to prove long-term safety or cure.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLAQUE PSORIASIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
UCSF Psoriasis and Skin Treatment Center
San Francisco, California, 94118, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new injection clear psoriasis when other biologics fail?
- Can a gel tame psoriasis? new antibody fragment put to the test
- Can a Once-Daily cream tame psoriasis in toddlers?
- Can a new drug called ZP9830 calm psoriasis Flare-Ups?
- Can we predict psoriasis relapse after biologics? a new study digs into the clues.
- New oral pill TLL018 aims to clear psoriasis plaques in phase 2 trial